Brought to you by 
ArGEN-X grosses €40mm in Euronext Brussels IPO
09 Jul 2014
Executive Summary
Floating on Euronext Brussels, Dutch antibody drug discovery company arGEN-X BV grossed €40mm ($54mm) in its IPO of 4.7mm shares at €8.50 (the bottom end of its €8.50-10.25 range). Belgian retail investors bought 6.2% of the stock, and existing arGEN-X backers committed to purchasing shares worth €10mm.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
ArGEN-X grosses €40mm in Euronext Brussels IPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice